ANAPTYSBIO, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
ANAPTYSBIO, INC. (ANAB) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $4.45 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2024-03-11
- ANAPTYSBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $4.45M.
- ANAPTYSBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was -$4.82M.
- ANAPTYSBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2021 was -$418.00K.
- ANAPTYSBIO, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2020 was -$342.00K, a 160.96% decline from fiscal 2019.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month as first filed |
|---|---|---|
| 2023-12-31 | $4.45M 10-K · filed 2024-03-11 | |
| 2022-12-31 | -$4.82M 10-K · filed 2024-03-11 | |
| 2021-12-31 | -$418.00K 10-K · filed 2024-03-11 | |
| 2020-12-31 | -$342.00K 10-K · filed 2023-03-01 | |
| 2019-12-31 | $561.00K 10-K · filed 2022-03-07 | |
| 2018-12-31 | $203.00K 10-K · filed 2021-02-25 | $258.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | -$426.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |